The serum levels of CEA and CA153 were found to be significantly higher in patients with breast cancer compared with those with benign breast diseases, both before and after PSM (p < 0.001), while no significant difference was observed for CA125 (p = 0.070 and 0.633, respectively, before and after PSM). Here, CEACAM5 is linked to breast fibrocystic disease.